Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Dumping Cytokinetics, Inc. (CYTK)

It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren’t usually symmetrically distributed and index returns are more affected by a few outlier stocks (i.e. the FAANG stocks dominating and driving S&P 500 Index’s returns in recent years), more than 50% of the constituents of the Standard and Poor’s 500 Index underperform the benchmark. Hence, if you randomly pick a stock, there is more than 50% chance that you’d fail to beat the market. At the same time, the 30 most favored S&P 500 stocks by the hedge funds monitored by Insider Monkey generated a return of 15.1% over the last 12 months (vs. 5.6% gain for SPY), with 53% of these stocks outperforming the benchmark. Of course, hedge funds do make wrong bets on some occasions and these get disproportionately publicized on financial media, but piggybacking their moves can beat the broader market on average. That’s why we are going to go over recent hedge fund activity in Cytokinetics, Inc. (NASDAQ:CYTK).

Cytokinetics, Inc. (NASDAQ:CYTK) has experienced a decrease in hedge fund sentiment of late. CYTK was in 13 hedge funds’ portfolios at the end of September. There were 14 hedge funds in our database with CYTK holdings at the end of the previous quarter. Our calculations also showed that CYTK isn’t among the 30 most popular stocks among hedge funds.

Today there are numerous tools shareholders have at their disposal to size up stocks. Two of the best tools are hedge fund and insider trading signals. Our experts have shown that, historically, those who follow the best picks of the elite fund managers can trounce the broader indices by a superb amount (see the details here).

D. E. Shaw

Let’s take a gander at the latest hedge fund action encompassing Cytokinetics, Inc. (NASDAQ:CYTK).

What does the smart money think about Cytokinetics, Inc. (NASDAQ:CYTK)?

At the end of the third quarter, a total of 13 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of -7% from the second quarter of 2018. On the other hand, there were a total of 12 hedge funds with a bullish position in CYTK at the beginning of this year. With hedgies’ capital changing hands, there exists a few notable hedge fund managers who were increasing their stakes considerably (or already accumulated large positions).

CYTK_dec2018

More specifically, Biotechnology Value Fund / BVF Inc was the largest shareholder of Cytokinetics, Inc. (NASDAQ:CYTK), with a stake worth $51.1 million reported as of the end of September. Trailing Biotechnology Value Fund / BVF Inc was Lansdowne Partners, which amassed a stake valued at $26.1 million. Great Point Partners, Millennium Management, and D E Shaw were also very fond of the stock, giving the stock large weights in their portfolios.

Because Cytokinetics, Inc. (NASDAQ:CYTK) has experienced bearish sentiment from the entirety of the hedge funds we track, logic holds that there is a sect of hedge funds that decided to sell off their entire stakes in the third quarter. Interestingly, Ken Griffin’s Citadel Investment Group cut the largest position of the 700 funds monitored by Insider Monkey, worth an estimated $0.5 million in stock. Andrew Feldstein and Stephen Siderow’s fund, Blue Mountain Capital, also said goodbye to its stock, about $0 million worth. These moves are important to note, as aggregate hedge fund interest dropped by 1 funds in the third quarter.

Let’s check out hedge fund activity in other stocks similar to Cytokinetics, Inc. (NASDAQ:CYTK). We will take a look at Ennis, Inc. (NYSE:EBF), Global Indemnity Limited (NASDAQ:GBLI), Old Line Bancshares, Inc. (NASDAQ:OLBK), and One Liberty Properties, Inc. (NYSE:OLP). This group of stocks’ market valuations resemble CYTK’s market valuation.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
EBF 11 53495 0
GBLI 7 47327 2
OLBK 7 55120 -4
OLP 6 25637 -1
Average 7.75 45395 -0.75

View table here if you experience formatting issues.

As you can see these stocks had an average of 7.75 hedge funds with bullish positions and the average amount invested in these stocks was $45 million. That figure was $105 million in CYTK’s case. Ennis, Inc. (NYSE:EBF) is the most popular stock in this table. On the other hand One Liberty Properties, Inc. (NYSE:OLP) is the least popular one with only 6 bullish hedge fund positions. Compared to these stocks Cytokinetics, Inc. (NASDAQ:CYTK) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...